相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cooperative roles for emmprin and LYVE-1 in the regulation of chemoresistance for primary effusion lymphoma
Z. Qin et al.
LEUKEMIA (2011)
Amplification of the Angiogenic Signal through the Activation of the TSC/mTOR/HIF Axis by the KSHV vGPCR in Kaposi's Sarcoma
Bruno C. Jham et al.
PLOS ONE (2011)
Cancer Incidence in the Multicenter AIDS Cohort Study Before and During the HAART Era
Eric C. Seaberg et al.
CANCER (2010)
Receptor Activator of NF-κB Ligand Enhances Breast Cancer-Induced Osteolytic Lesions through Upregulation of Extracellular Matrix Metalloproteinase Inducer/CD147
Nadia Rucci et al.
CANCER RESEARCH (2010)
Direct Activation of Emmprin and Associated Pathogenesis by an Oncogenic Herpesvirus
Zhiqiang Qin et al.
CANCER RESEARCH (2010)
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways
Sandra E. Ghayad et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-κB and MKK7/JNK/AP-1 signaling
Balachandar Venkatesan et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2010)
Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV
Zhigiang Qin et al.
VIROLOGY (2010)
EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2α-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2
Faten Bougatef et al.
BLOOD (2009)
Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy
Sherif Daouti et al.
CANCER RESEARCH (2009)
Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy
Hai-Yan Zhang et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2009)
Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia
Alberto M. Martelli et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response
Huong Q. Nguyen et al.
AIDS (2008)
Resveratrol inhibits EMMPRIN expression via p38 and ERK1/2 pathways in PMA-induced THP-1 cells
Zhouqing Huang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells
Xianling Guo et al.
BMC CANCER (2008)
Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells
Ling Wang et al.
CANCER RESEARCH (2008)
Suppression of dendritic cell differentiation through cytokines released by Primary Effusion Lymphoma cells
Mara Cirone et al.
IMMUNOLOGY LETTERS (2008)
Basigin-2 is a cell surface receptor for soluble basigin ligand
Robert J. Belton et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
An NF-κB gene expression signature contributes to Kaposi's sarcoma virus vGPCR-induced direct and paracrine neoplasia
D. Martin et al.
ONCOGENE (2008)
Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinasesv
Li-Wu Qian et al.
JOURNAL OF VIROLOGY (2007)
Kaposi's sarcoma-associated herpesvirus induces sustained NF-κB activation during de novo infection of primary human dermal microvascular endothelial cells that is essential for viral gene expression
Sathish Sadagopan et al.
JOURNAL OF VIROLOGY (2007)
Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway
Yi Tang et al.
MOLECULAR CANCER RESEARCH (2006)
Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-κB activation
Q Sun et al.
ONCOGENE (2006)
Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: An AIDS Malignancy Consortium study
BJ Dezube et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model
A Ferrario et al.
JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY (2006)
Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine
MB Nilsson et al.
CANCER RESEARCH (2005)
Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and P13-Kinase/Akt pathways
SH Jee et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia
S Montaner et al.
BLOOD (2004)
Regulation of multidrug resistance in cancer cells by hyaluronan
S Misra et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR
C Bais et al.
CANCER CELL (2003)
Activation of NF-κB by the human herpesvirus 8 chemokine receptor ORF74:: Evidence for a paracrine model of Kaposi's sarcoma pathogenesis
S Pati et al.
JOURNAL OF VIROLOGY (2001)
Interleukin-6 is a growth factor for nonmalignant human plasmablasts
G Jego et al.
BLOOD (2001)
Activity of thalidomide in AIDS-related Kaposis's sarcoma
RF Little et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
